Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05286801CT.gov Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atypical Teratoid Rhabdoid Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | National Cancer Institute (NCI) | P1/2 | CCC · 48 |
| Tazemetostat | Epizyme, Inc. | P2 | B |
| Thalidomide | Medical University of Vienna | P2 | CCC |
| Fenofibric Acid | Medical University of Vienna | P2 | CCC |
| Cyclophosphamide | Medical University of Vienna | P2 | CCC |
| Celecoxib | Medical University of Vienna | P2 | CCC |
| Irinotecan | Medical University of Vienna | P2 | CCC |
| Cytarabine | Medical University of Vienna | P2 | CCC |
| Etoposide | Medical University of Vienna | P2 | CCC |
+30 more in the Atypical Teratoid Rhabdoid Tumor cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atezolizumab in Atypical Teratoid Rhabdoid Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-atypical-teratoid-rhabdoid-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →